Attenuated vaccine explained

An attenuated vaccine (or a live attenuated vaccine, LAV) is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live").[1] Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent.[2] These vaccines contrast to those produced by "killing" the pathogen (inactivated vaccine).

Attenuated vaccines stimulate a strong and effective immune response that is long-lasting.[3] In comparison to inactivated vaccines, attenuated vaccines produce a stronger and more durable immune response with a quick immunity onset.[4] [5] [6] They are generally avoided in pregnancy and in patients with severe immunodeficiencies.[7] Attenuated vaccines function by encouraging the body to create antibodies and memory immune cells in response to the specific pathogen which the vaccine protects against. Common examples of live attenuated vaccines are measles, mumps, rubella, yellow fever, and some influenza vaccines.[3]

Development

Attenuated viruses

Viruses may be attenuated using the principles of evolution with serial passage of the virus through a foreign host species, such as:[8] [9]

The initial virus population is applied to a foreign host. Through natural genetic variability or induced mutation, a small percentage of the viral particles should have the capacity to infect the new host.[10] These strains will continue to evolve within the new host and the virus will gradually lose its efficacy in the original host, due to lack of selection pressure. This process is known as "passage" in which the virus becomes so well adapted to the foreign host that it is no longer harmful to the subject that is to receive the vaccine. This makes it easier for the host immune system to eliminate the agent and create the immunological memory cells which will likely protect the patient if they are infected with a similar version of the virus in "the wild".

Viruses may also be attenuated via reverse genetics.[11] Attenuation by genetics is also used in the production of oncolytic viruses.[12]

Attenuated bacteria

Bacteria is typically attenuated by passage, similar to the method used in viruses.[13] Gene knockout guided by reverse genetics is also used.[14]

Administration

Attenuated vaccines can be administered in a variety of ways:

Oral vaccines or subcutaneous/intramuscular injection are for individuals older than 12 months. Live attenuated vaccines, with the exception of the rotavirus vaccine given at 6 weeks, is not indicated for infants younger than 9 months.[18]

Mechanism

Vaccines function by encouraging the creation of immune cells, such as CD8+ and CD4+ T lymphocytes, or molecules, such as antibodies, that are specific to the pathogen.[19] The cells and molecules can either prevent or reduce infection by killing infected cells or by producing interleukins. The specific effectors evoked can be different based on the vaccine. Live attenuated vaccines tend to help with the production of CD8+ cytotoxic T lymphocytes and T-dependent antibody responses. A vaccine is only effective for as long as the body maintains a population of these cells.

Attenuated vaccines are “weakened” versions of pathogens (virus or bacteria). They are modified so that it cannot cause harm or disease in the body but are still able to activate the immune system.[20] This type of vaccine works by activating both the cellular and humoral immune responses of the adaptive immune system. When a person receives an oral or injection of the vaccine, B cells, which help make antibodies, are activated in two ways: T cell-dependent and T-cell independent activation.[21]

In T-cell dependent activation of B cells, B cells first recognize and present the antigen on MHCII receptors. T-cells can then recognize this presentation and bind to the B cell, resulting in clonal proliferation. This also helps IgM and plasma cells production as well as immunoglobulin switching. On the other hand, T-cell independent activation of B cells is due to non-protein antigens. This can lead to production of IgM antibodies. Being able to produce a B-cell response as well as memory killer T cells is a key feature of attenuated virus vaccines that help induce a potent immunity.

Safety

Live-attenuated vaccines are safe and stimulate a strong and effective immune response that is long-lasting.[3] Given pathogens are attenuated, it is extremely rare for pathogens to revert to their pathogenic form and subsequently cause disease.[22] Additionally, within the five WHO-recommended live attenuated vaccines (tuberculosis, oral polio, measles, rotavirus, and yellow fever), severe adverse reactions are extremely rare.

Individuals with severely compromised immune systems (e.g., HIV-infection, chemotherapy, immunosuppressive therapy, lymphoma, leukemia, combined immunodeficiencies) typically should not receive live-attenuated vaccines as they may not be able to produce an adequate and safe immune response.[3] [22] [23] Household contacts of immunodeficient individuals are still able to receive most attenuated vaccines since there is no increased risk of infection transmission, with the exception being the oral polio vaccine.

As precaution, live-attenuated vaccines are not typically administered during pregnancy. This is due to the risk of transmission of virus between mother and fetus. In particular, the varicella and yellow fever vaccines have been shown to have adverse effects on fetuses and nursing babies.

Some live attenuated vaccines have additional common, mild adverse effects due to their administration route. For example, the live attenuated influenza vaccine is given nasally and is associated with nasal congestion.

Compared to inactivated vaccines, live-attenuated vaccines are more prone to immunization errors as they must be kept under strict conditions during the cold chain and carefully prepared (e.g., during reconstitution).[3] [22]

History

The history of vaccine development started with the creation of the smallpox vaccine by Edward Jenner in the late 18th century.[24] Jenner discovered that inoculating a human with an animal pox virus would grant immunity against smallpox, a disease considered to be one of the most devastating in human history.[25] Although the original smallpox vaccine is sometimes considered to be an attenuated vaccine due to its live nature, it was not strictly-speaking attenuated since it was not derived directly from smallpox. Instead, it was based on the related and milder cowpox disease.[26] The discovery that diseases could be artificially attenuated came in the late 19th century when Louis Pasteur was able to derive an attenuated strain of chicken cholera. Pasteur applied this knowledge to develop an attenuated anthrax vaccine and demonstrating its effectiveness in a public experiment.[27] The first rabies vaccine was subsequently produced by Pasteur and Emile Roux by growing the virus in rabbits and drying the affected nervous tissue.

The technique of cultivating a virus repeatedly in artificial media and isolating less virulent strains was pioneered in the early 20th century by Albert Calmette and Camille Guérin who developed an attenuated tuberculosis vaccine called the BCG vaccine. This technique was later used by several teams when developing the vaccine for yellow fever, first by Sellards and Laigret, and then by Theiler and Smith.[28] The vaccine developed by Theiler and Smith proved to be hugely successful and helped establish recommended practices and regulations for many other vaccines. These include the growth of viruses in primary tissue culture (e.g., chick embryos), as opposed to animals, and the use of the seed stock system which uses the original attenuated viruses as opposed to derived viruses (done to reduce variance in vaccine development and decrease the chance of adverse effects). The middle of the 20th century saw the work of many prominent virologists including Sabin, Hilleman, and Enders, and the introduction of several successful attenuated vaccines, such as those against polio, measles, mumps, and rubella.[29] [30] [31] [32]

Advantages and disadvantages

Advantages

Disadvantages

List of attenuated vaccines

Currently in-use

For many of the pathogens listed below there are many vaccines, the list below simply indicates that there are one (or more) attenuated vaccines for that particular pathogen, not that all vaccines for that pathogen are attenuated.

Bacterial vaccines

Viral vaccines

In development

Bacterial vaccines

Viral vaccines

External links

Notes and References

  1. Badgett. Marty R.. Auer. Alexandra. Carmichael. Leland E.. Parrish. Colin R.. Bull. James J.. October 2002. Evolutionary Dynamics of Viral Attenuation. Journal of Virology. 76. 20. 10524–10529. 10.1128/JVI.76.20.10524-10529.2002. 0022-538X. 12239331. 136581.
  2. Pulendran. Bali. Ahmed. Rafi. June 2011. Immunological mechanisms of vaccination. Nature Immunology. 12. 6. 509–517. 10.1038/ni.2039. 1529-2908. 3253344. 21739679.
  3. Web site: Vaccine Types Vaccines. 2020-11-16. www.vaccines.gov. 23 May 2019. https://web.archive.org/web/20190523191043/https://www.vaccines.gov/basics/types. live.
  4. Gil. Carmen. Latasa. Cristina. García-Ona. Enrique. Lázaro. Isidro. Labairu. Javier. Echeverz. Maite. Burgui. Saioa. García. Begoña. Lasa. Iñigo. Solano. Cristina. 2020. A DIVA vaccine strain lacking RpoS and the secondary messenger c-di-GMP for protection against salmonellosis in pigs. Veterinary Research. 51. 1. 3. 10.1186/s13567-019-0730-3. 0928-4249. 6954585. 31924274 . free .
  5. Tretyakova. Irina. Lukashevich. Igor S.. Glass. Pamela. Wang. Eryu. Weaver. Scott. Pushko. Peter. 2013-02-04. Novel Vaccine against Venezuelan Equine Encephalitis Combines Advantages of DNA Immunization and a Live Attenuated Vaccine. Vaccine. 31. 7. 1019–1025. 10.1016/j.vaccine.2012.12.050. 0264-410X. 3556218. 23287629.
  6. Zou. Jing. Xie. Xuping. Luo. Huanle. Shan. Chao. Muruato. Antonio E.. Weaver. Scott C.. Wang. Tian. Shi. Pei-Yong. 2018-09-07. A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity. eBioMedicine. 36. 92–102. 10.1016/j.ebiom.2018.08.056. 2352-3964. 6197676. 30201444.
  7. Web site: 2023-09-19 . ACIP Altered Immunocompetence Guidelines for Immunizations CDC . 2023-09-26 . www.cdc.gov . en-us . 26 September 2023 . https://web.archive.org/web/20230926204846/https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html . live .
  8. Jordan. Ingo. Sandig. Volker. 2014-04-11. Matrix and Backstage: Cellular Substrates for Viral Vaccines. Viruses. 6. 4. 1672–1700. 10.3390/v6041672. 1999-4915. 4014716. 24732259. free.
  9. Book: 2015. Nunnally. Brian K.. Turula. Vincent E.. Sitrin. Robert D.. Vaccine Analysis: Strategies, Principles, and Control. en-gb. 10.1007/978-3-662-45024-6. 978-3-662-45023-9. 39542692. 3 November 2020. 25 January 2023. https://web.archive.org/web/20230125193900/https://link.springer.com/book/10.1007/978-3-662-45024-6. live.
  10. Hanley. Kathryn A.. December 2011. The double-edged sword: How evolution can make or break a live-attenuated virus vaccine. Evolution. 4. 4. 635–643. 10.1007/s12052-011-0365-y. 1936-6426. 3314307. 22468165.
  11. Nogales. Aitor. Martínez-Sobrido. Luis. 2016-12-22. Reverse Genetics Approaches for the Development of Influenza Vaccines. International Journal of Molecular Sciences. 18. 1. 20. 10.3390/ijms18010020. 1422-0067. 5297655. 28025504. free.
  12. Gentry GA . Viral thymidine kinases and their relatives . Pharmacology & Therapeutics . 54 . 3 . 319–55 . 1992 . 1334563 . 10.1016/0163-7258(92)90006-L.
  13. Web site: Immunology and Vaccine-Preventable Diseases . CDC . 9 December 2020 . 8 April 2020 . https://web.archive.org/web/20200408173837/https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf . live .
  14. Xiong . Kun . Zhu . Chunyue . Chen . Zhijin . Zheng . Chunping . Tan . Yong . Rao . Xiancai . Cong . Yanguang . Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi . Frontiers in Cellular and Infection Microbiology . 24 April 2017 . 7 . 135 . 10.3389/fcimb.2017.00135. 28484685 . 5401900 . free .
  15. Herzog. Christian. 2014. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Review of Vaccines. en. 13. 3. 399–415. 10.1586/14760584.2014.883285. 24512188. 46577849. 1476-0584. 16 November 2020. 25 January 2023. https://web.archive.org/web/20230125193859/https://www.tandfonline.com/doi/full/10.1586/14760584.2014.883285. live.
  16. Gasparini. R.. Amicizia. D.. Lai. P. L.. Panatto. D.. 2011. Live attenuated influenza vaccine--a review. Journal of Preventive Medicine and Hygiene. 52. 3. 95–101. 1121-2233. 22010534. 16 November 2020. 25 January 2023. https://web.archive.org/web/20230125193859/https://pubmed.ncbi.nlm.nih.gov/22010534/. live.
  17. Book: Morrow, W. John W.. Vaccinology : Principles and Practice.. 2012. John Wiley & Sons. Sheikh, Nadeem A., Schmidt, Clint S., Davies, D. Huw.. 978-1-118-34533-7. Hoboken. 795120561.
  18. Web site: Your Child's Immunizations: Rotavirus Vaccine (RV) (for Parents) - Nemours KidsHealth . 2022-09-15 . kidshealth.org . 25 January 2023 . https://web.archive.org/web/20230125193900/https://kidshealth.org/en/parents/rotavirus-vaccine.html . live .
  19. Book: Plotkin's vaccines. Plotkin, Stanley A., 1932-, Orenstein, Walter A.,, Offit, Paul A.. 2018. 978-0-323-39302-7. Seventh. Philadelphia, PA. 989157433.
  20. Web site: 2021-04-26 . Vaccine Types . live . https://web.archive.org/web/20210716125750/https://www.hhs.gov/immunization/basics/types/index.html . 16 July 2021 . 2022-09-15 . HHS.gov . en.
  21. Book: Sompayrac, Lauren . How the immune system works . 2019 . 978-1-119-54212-4 . Sixth . Hoboken, NJ . 1083261548.
  22. Web site: MODULE 2 – Live attenuated vaccines (LAV) - WHO Vaccine Safety Basics. 2020-11-16. vaccine-safety-training.org. 12 November 2020. https://web.archive.org/web/20201112032856/https://vaccine-safety-training.org/live-attenuated-vaccines.html. live.
  23. Sobh. Ali. Bonilla. Francisco A.. Nov 2016. Vaccination in Primary Immunodeficiency Disorders. The Journal of Allergy and Clinical Immunology: In Practice. en. 4. 6. 1066–1075. 10.1016/j.jaip.2016.09.012. 27836056. 17 November 2020. 25 January 2023. https://web.archive.org/web/20230125193907/https://www.jaci-inpractice.org/article/S2213-2198(16)30408-1/fulltext. live.
  24. Plotkin. Stanley. 2014-08-26. History of vaccination. Proceedings of the National Academy of Sciences of the United States of America. 111. 34. 12283–12287. 10.1073/pnas.1400472111. 1091-6490. 4151719. 25136134. 2014PNAS..11112283P. free.
  25. Eyler. John M.. October 2003. Smallpox in history: the birth, death, and impact of a dread disease. Journal of Laboratory and Clinical Medicine. 142. 4. 216–220. 10.1016/s0022-2143(03)00102-1. 14625526. 0022-2143. 23 November 2020. 25 January 2023. https://web.archive.org/web/20230125173506/https://www.translationalres.com/article/S0022-2143(03)00102-1/fulltext. live.
  26. 2015-05-01. Live attenuated vaccines: Historical successes and current challenges. Virology. en. 479-480. 379–392. 10.1016/j.virol.2015.03.032. 0042-6822. Minor. Philip D.. 25864107. free.
  27. Schwartz. M.. 7 July 2008. The life and works of Louis Pasteur. Journal of Applied Microbiology. 91. 4. 597–601. 10.1046/j.1365-2672.2001.01495.x. 1364-5072. 11576293. 39020116.
  28. Frierson. J. Gordon. June 2010. The Yellow Fever Vaccine: A History. The Yale Journal of Biology and Medicine. 83. 2. 77–85. 0044-0086. 2892770. 20589188.
  29. Shampo. Marc A.. Kyle. Robert A.. Steensma. David P.. July 2011. Albert Sabin—Conqueror of Poliomyelitis. Mayo Clinic Proceedings. 86. 7. e44. 10.4065/mcp.2011.0345. 0025-6196. 3127575. 21719614.
  30. Newman. Laura. 2005-04-30. Maurice Hilleman. BMJ: British Medical Journal. 330. 7498. 1028. 10.1136/bmj.330.7498.1028. 557162. 0959-8138.
  31. Book: Katz, S. L.. Measles. John F. Enders and Measles Virus Vaccine—a Reminiscence. Current Topics in Microbiology and Immunology. 2009. https://pubmed.ncbi.nlm.nih.gov/19198559/. 329. 3–11. 10.1007/978-3-540-70523-9_1. 0070-217X. 19198559. 978-3-540-70522-2. 2884917. 23 November 2020. 27 January 2021. https://web.archive.org/web/20210127194814/https://pubmed.ncbi.nlm.nih.gov/19198559/. live.
  32. Plotkin. Stanley A.. 2006-11-01. The History of Rubella and Rubella Vaccination Leading to Elimination. Clinical Infectious Diseases. en. 43. Supplement_3. S164–S168. 10.1086/505950. 16998777. 1058-4838. free.
  33. Vetter. Volker. Denizer. Gülhan. Friedland. Leonard R.. Krishnan. Jyothsna. Shapiro. Marla. 2018-02-17. Understanding modern-day vaccines: what you need to know. Annals of Medicine. 50. 2. 110–120. 10.1080/07853890.2017.1407035. 0785-3890. 29172780. 25514266. free.
  34. Minor. Philip D.. May 2015. Live attenuated vaccines: Historical successes and current challenges. Virology. 479-480. 379–392. 10.1016/j.virol.2015.03.032. 1096-0341. 25864107. free.
  35. Benn. Christine S.. Netea. Mihai G.. Selin. Liisa K.. Aaby. Peter. September 2013. A small jab – a big effect: nonspecific immunomodulation by vaccines. Trends in Immunology. 34. 9. 431–439. 10.1016/j.it.2013.04.004. 23680130.
  36. etal. Shimizu H, Thorley B, Paladin FJ. December 2004. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol.. 78. 24. 13512–21. 10.1128/JVI.78.24.13512-13521.2004. 533948. 15564462.
  37. News: Kroger. Andrew T.. Ciro V. Sumaya. Larry K. Pickering. William L. Atkinson. 2011-01-28. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR). Centers for Disease Control and Prevention. 2011-03-11. 10 July 2017. https://web.archive.org/web/20170710182317/https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm?s_cid=rr6002a1_e. live.
  38. Cheuk. Daniel KL. Chiang. Alan KS. Lee. Tsz Leung. Chan. Godfrey CF. Ha. Shau Yin. 2011-03-16. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database of Systematic Reviews. 3. CD006505. 10.1002/14651858.cd006505.pub2. 21412895. 1465-1858.
  39. Levine. Myron M.. 2011-12-30. "IDEAL" vaccines for resource poor settings. Vaccine. Smallpox Eradication after 30 Years: Lessons, Legacies and Innovations. en. 29. D116–D125. 10.1016/j.vaccine.2011.11.090. 22486974. 0264-410X.
  40. Donegan. Sarah. Bellamy. Richard. Gamble. Carrol L. 2009-04-15. Vaccines for preventing anthrax. Cochrane Database of Systematic Reviews. 2009 . 2. CD006403. 10.1002/14651858.cd006403.pub2. 1465-1858. 6532564. 19370633.
  41. Harris. Jason B. 2018-11-15. Cholera: Immunity and Prospects in Vaccine Development. The Journal of Infectious Diseases. 218. Suppl 3. S141–S146. 10.1093/infdis/jiy414. 0022-1899. 6188552. 30184117.
  42. Verma. Shailendra Kumar. Tuteja. Urmil. 2016-12-14. Plague Vaccine Development: Current Research and Future Trends. Frontiers in Immunology. 7. 602. 10.3389/fimmu.2016.00602. 1664-3224. 5155008. 28018363. free.
  43. Odey. Friday. Okomo. Uduak. Oyo-Ita. Angela. 2018-12-05. Vaccines for preventing invasive salmonella infections in people with sickle cell disease. Cochrane Database of Systematic Reviews. 12. 4. CD006975. 10.1002/14651858.cd006975.pub4. 1465-1858. 6517230. 30521695.
  44. Schrager. Lewis K.. Harris. Rebecca C.. Vekemans. Johan. 2019-02-24. Research and development of new tuberculosis vaccines: a review. F1000Research. 7. 1732. 10.12688/f1000research.16521.2. 2046-1402. 6305224. 30613395 . free .
  45. Meiring. James E. Giubilini. Alberto. Savulescu. Julian. Pitzer. Virginia E. Pollard. Andrew J. 2019-11-01. Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge. Clinical Infectious Diseases. 69. Suppl 5. S402–S407. 10.1093/cid/ciz630. 1058-4838. 6792111. 31612941.
  46. Jefferson. Tom. Rivetti. Alessandro. Di Pietrantonj. Carlo. Demicheli. Vittorio. 2018-02-01. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews. 2018. 2 . CD004879. 10.1002/14651858.cd004879.pub5. 1465-1858. 6491174. 29388195.
  47. Yun. Sang-Im. Lee. Young-Min. 2014-02-01. Japanese encephalitis. Human Vaccines & Immunotherapeutics. 10. 2. 263–279. 10.4161/hv.26902. 2164-5515. 4185882. 24161909.
  48. Griffin. Diane E.. 2018-03-01. Measles Vaccine. Viral Immunology. 31. 2. 86–95. 10.1089/vim.2017.0143. 0882-8245. 5863094. 29256824.
  49. Su. Shih-Bin. Chang. Hsiao-Liang. Chen. And Kow-Tong. 5 March 2020. Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine. International Journal of Environmental Research and Public Health. 17. 5. 1686. 10.3390/ijerph17051686. 1660-4601. 7084951. 32150969. free.
  50. May 2014. Observed Rate of Vaccine Reactions – Measles, Mumps and Rubella Vaccines. World Health Organization Information Sheet. 2 November 2020. 17 December 2019. https://web.archive.org/web/20191217095809/https://www.who.int/vaccine_safety/initiative/tools/MMR_vaccine_rates_information_sheet.pdf. live.
  51. Di Pietrantonj. Carlo. Rivetti. Alessandro. Marchione. Pasquale. Debalini. Maria Grazia. Demicheli. Vittorio. April 20, 2020. Vaccines for measles, mumps, rubella, and varicella in children. The Cochrane Database of Systematic Reviews. 4. 4 . CD004407. 10.1002/14651858.CD004407.pub4. 1469-493X. 7169657. 32309885.
  52. Bandyopadhyay. Ananda S.. Garon. Julie. Seib. Katherine. Orenstein. Walter A.. 2015. Polio vaccination: past, present and future. Future Microbiology. 10. 5. 791–808. 10.2217/fmb.15.19. 1746-0921. 25824845. free.
  53. Bruijning-Verhagen. Patricia. Groome. Michelle. July 2017. Rotavirus Vaccine: Current Use and Future Considerations. The Pediatric Infectious Disease Journal. 36. 7. 676–678. 10.1097/INF.0000000000001594. 1532-0987. 28383393. 41278475. 2 November 2020. 25 January 2023. https://web.archive.org/web/20230125194530/https://pubmed.ncbi.nlm.nih.gov/28383393/. live.
  54. Lambert. Nathaniel. Strebel. Peter. Orenstein. Walter. Icenogle. Joseph. Poland. Gregory A.. 2015-06-06. Rubella. Lancet. 385. 9984. 2297–2307. 10.1016/S0140-6736(14)60539-0. 0140-6736. 4514442. 25576992.
  55. Voigt. Emily A.. Kennedy. Richard B.. Poland. Gregory A.. September 2016. Defending against smallpox: a focus on vaccines. Expert Review of Vaccines. 15. 9. 1197–1211. 10.1080/14760584.2016.1175305. 1744-8395. 5003177. 27049653.
  56. Marin. Mona. Marti. Melanie. Kambhampati. Anita. Jeram. Stanley M.. Seward. Jane F.. March 1, 2016. Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics. 137. 3. e20153741. 10.1542/peds.2015-3741. 1098-4275. 26908671. 25263970. free.
  57. Monath. Thomas P.. Vasconcelos. Pedro F. C.. March 2015. Yellow fever. Journal of Clinical Virology. 64. 160–173. 10.1016/j.jcv.2014.08.030. 1873-5967. 25453327. 5124080. 2 November 2020. 25 January 2023. https://web.archive.org/web/20230125194530/https://pubmed.ncbi.nlm.nih.gov/25453327/. live.
  58. Schmader. Kenneth. August 7, 2018. Herpes Zoster. Annals of Internal Medicine. 169. 3. ITC19–ITC31. 10.7326/AITC201808070. 1539-3704. 30083718. 51926613. 2 November 2020. 24 October 2022. https://web.archive.org/web/20221024134519/https://pubmed.ncbi.nlm.nih.gov/30083718/. live.
  59. Mirhoseini. Ali. Amani. Jafar. Nazarian. Shahram. April 2018. Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it. Microbial Pathogenesis. 117. 162–169. 10.1016/j.micpath.2018.02.032. 1096-1208. 29474827. 2 November 2020. 23 January 2023. https://web.archive.org/web/20230123231903/https://pubmed.ncbi.nlm.nih.gov/29474827/. live.
  60. Kubinski. Mareike. Beicht. Jana. Gerlach. Thomas. Volz. Asisa. Sutter. Gerd. Rimmelzwaan. Guus F.. 2020-08-12. Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise. Vaccines. 8. 3. 451. 10.3390/vaccines8030451. 2076-393X. 7564546. 32806696. free.
  61. Web site: Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19 . ClinicalTrials.gov . United States National Library of Medicine . 8 June 2021 . 22 January 2021 . https://web.archive.org/web/20210122001432/https://clinicaltrials.gov/ct2/show/NCT04619628 . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Attenuated vaccine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.